Evenity (Romosozumab) Cannabis Interaction Profile

What Is Romosozumab and Why Does the Interaction Profile Matter?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a protein secreted by osteocytes that normally suppresses bone formation. By blocking sclerostin, Evenity simultaneously increases bone formation markers and decreases bone resorption markers, a dual mechanism unique among approved osteoporosis therapies. The FDA approved it in April 2019 for postmenopausal women with osteoporosis at high fracture risk, defined as a prior osteoporotic fracture, very low T-score, or failure of prior therapy [1].

The interaction profile matters for one specific reason: the FDA mandated a boxed warning citing a significantly higher rate of serious cardiovascular events observed in the ARCH trial (N=4,093), where romosozumab 210 mg monthly for 12 months produced 2.5% major adverse cardiac events (MACE) vs. 1.9% for alendronate (hazard ratio 1.87, 95% CI 1.10 to 3.17) [2]. Any substance that independently adds cardiovascular stress compounds this concern.

How Romosozumab Is Metabolized

Romosozumab is a large-molecule monoclonal antibody. Like other IgG2 biologics, it undergoes proteolytic degradation into peptides and amino acids. It is not processed by hepatic CYP450 enzymes, P-glycoprotein, or renal tubular transporters [1]. This means classical pharmacokinetic drug-drug interactions (the kind seen with small-molecule drugs competing for CYP3A4) do not apply here.

Why This Distinction Is Clinically Relevant

Because romosozumab bypasses hepatic drug-metabolizing enzymes entirely, the concern with cannabis is not about altered romosozumab blood levels. Prescribers and patients sometimes assume "no CYP interaction" means "no interaction at all." That conclusion is incorrect. Pharmacodynamic interactions, where two agents affect the same physiological system through different mechanisms, can occur even when pharmacokinetics are clean.

Cannabis Pharmacology: THC, CBD, and the Cardiovascular System

Cannabis contains more than 100 cannabinoids. The two most clinically relevant are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). They have meaningfully different pharmacological profiles and produce different risks in the context of romosozumab therapy.

THC and Acute Cardiovascular Stress

THC binds CB1 receptors in the central nervous system and peripheral tissues, producing a predictable sympathomimetic surge followed by vasodilation and reflex tachycardia. Acute cannabis smoking raises heart rate by 20 to 100% above baseline within minutes, transiently elevates blood pressure, and increases cardiac oxygen demand [3]. A 2019 analysis in the Journal of the American Heart Association found that cannabis use was associated with a 1.5-fold increased risk of cardiovascular death and a 1.74-fold increased risk of stroke in adults over 18 [4].

In patients who already carry elevated baseline cardiovascular risk (the population most likely to receive romosozumab, given that postmenopausal women over 65 are the primary indicated group), layering acute THC-mediated sympathetic surges onto a drug with a confirmed MACE signal is a scenario that has not been tested in any registered trial.

CBD and CYP Enzyme Inhibition

CBD does not carry the same sympathomimetic profile as THC. At therapeutic doses used in pharmaceutical CBD (Epidiolex), CBD inhibits CYP2C9, CYP2C19, and CYP3A4, and it inhibits the drug transporter P-glycoprotein [5]. Because romosozumab is not a CYP substrate, CBD's enzyme-inhibitory activity is irrelevant to romosozumab levels specifically. However, patients on Evenity are often on concomitant medications: bisphosphonates post-Evenity sequencing agents like denosumab, calcium/vitamin D supplements, antihypertensives, and anticoagulants. CBD can raise plasma levels of warfarin, certain statins, and calcium-channel blockers, which may affect the overall cardiovascular risk picture indirectly.

Endocannabinoid System and Bone Metabolism

Bone cells express both CB1 and CB2 receptors, and the endocannabinoid system has a regulatory role in bone remodeling. CB2 receptor activation has been shown in preclinical models to reduce osteoclast activity and support bone mass [6]. THC acts on both CB1 and CB2. A 2021 study in the Journal of Bone and Mineral Research (JBMR) demonstrated that chronic THC exposure in a murine model reduced peak bone mass by approximately 10% compared to controls, a finding attributed to CB1-mediated suppression of osteoblast differentiation [7].

The clinical relevance is direct. Romosozumab's therapeutic value depends on strong anabolic bone formation signaling. If chronic cannabis use dampens osteoblast function through CB1 agonism, the anabolic response to romosozumab may be attenuated. This has not been tested in a human clinical trial as of mid-2025.

The Cardiovascular Warning: Why It Changes the Calculus

The ARCH trial compared romosozumab 210 mg SC monthly (12 months) followed by alendronate vs. Alendronate alone in 4,093 postmenopausal women with osteoporosis and prior vertebral fracture. The primary efficacy outcome was favorable: romosozumab reduced new vertebral fracture risk by 48% (6.2% vs. 11.9%, P<0.001) [2]. The cardiovascular signal was the cost.

The FDA's prescribing label states directly: "Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year" [1]. Prescribers are instructed to weigh benefit against cardiovascular risk for all patients with cardiac history.

The HealthRX clinical team uses the following three-tier framework when a patient on Evenity asks about cannabis:

Tier 1 (Low Risk). No prior cardiovascular events, blood pressure consistently below 130/80 mmHg, non-smoking status, cannabis use limited to occasional low-dose oral/sublingual CBD products. Counsel on theoretical bone-metabolism concern; no hard contraindication to continued use; document discussion.

Tier 2 (Moderate Risk). One cardiovascular risk factor (hypertension, dyslipidemia, or diabetes) but no prior MACE. Cannabis use involves regular THC-dominant products (smoked, vaped, or high-dose edibles). Recommend reducing or pausing cannabis during the 12-month romosozumab course. Monitor blood pressure and heart rate at each monthly injection visit.

Tier 3 (High Risk). Prior MI or stroke within 12 months (romosozumab is contraindicated regardless). Prior MI or stroke greater than 12 months ago, or two or more cardiovascular risk factors combined with regular cannabis use. Strong recommendation to discontinue cannabis for the duration of treatment; consider whether romosozumab is the appropriate choice vs. An alternative anabolic agent such as teriparatide or abaloparatide.

Can You Drink Alcohol While on Evenity?

This question reaches our clinical team frequently. The answer requires separating two distinct concerns.

Alcohol and Bone Metabolism

Chronic heavy alcohol consumption, defined as more than 14 standard drinks per week in the NIAAA framework, directly suppresses osteoblast proliferation, reduces calcium absorption from the gut, elevates cortisol (which accelerates bone loss), and increases fall risk [8]. A meta-analysis in Osteoporosis International (2012) found that heavy alcohol use was associated with a 28% increased risk of any osteoporotic fracture compared to non-drinkers [9].

For a patient on romosozumab precisely because their fracture risk is already high, heavy alcohol use during treatment actively works against the medication's goal. The 12-month window of romosozumab-induced bone formation is not renewable: the FDA-approved course is a single 12-month period (12 injections of 210 mg each), and the anabolic window closes after that. Undermining it with chronic alcohol use is a decision with long-term consequences.

Alcohol and Cardiovascular Risk

Moderate alcohol (1 drink/day for women, per the 2020 Dietary Guidelines for Americans) does not carry the same acute cardiovascular burden as THC. Heavy episodic drinking, however, does. Binge drinking triggers sympathetic surges, atrial arrhythmias ("holiday heart"), and transient hypertension, all of which overlap with romosozumab's existing cardiovascular risk profile [10].

Practical Guidance on Alcohol

Light to moderate drinking (1 drink/day or fewer) is not formally contraindicated during romosozumab therapy. Heavy or binge drinking is strongly discouraged given both the bone-metabolism interference and the cardiovascular risk overlap. Patients should discuss their actual intake levels honestly with their prescriber during the monthly injection visits.

Drug-Drug Interactions: The Broader Romosozumab Picture

While the cannabis question is the focus here, contextualizing it within the full romosozumab interaction profile helps clinicians and patients see where cannabis fits on the risk spectrum.

Calcium and Vitamin D Supplementation

Romosozumab increases bone formation rapidly. This demands adequate substrate. The Endocrine Society's 2019 clinical practice guideline on postmenopausal osteoporosis recommends 1,000 to 1,200 mg/day elemental calcium and 800 to 1,000 IU/day vitamin D for patients on anabolic bone therapy [11]. Failure to supplement adequately can cause hypocalcemia, particularly in patients with vitamin D deficiency at baseline. Cannabis and alcohol do not directly interfere with calcium metabolism at typical recreational doses, though chronic heavy alcohol use does reduce gut calcium absorption [8].

Sequential Antiresorptive Therapy

Romosozumab's anabolic gains are substantially lost without immediate follow-on antiresorptive therapy. In the FRAME trial (N=7,180), patients who transitioned from romosozumab to denosumab maintained a 15.0% increase in lumbar spine BMD at 24 months from baseline, while patients transitioned to placebo lost the majority of their BMD gain [12]. Patients should understand that cannabis-related lifestyle decisions during the 12-month anabolic window also affect the durability of the follow-on treatment phase.

NSAIDs, Anticoagulants, and Antihypertensives

These are among the most common concomitant medications in the postmenopausal, osteoporosis-diagnosed population. Romosozumab itself does not pharmacokinetically interact with them. CBD, however, can inhibit warfarin metabolism via CYP2C9, potentially raising INR and bleeding risk. Patients using both CBD products and anticoagulants should be monitored more closely for bleeding events.

What the FDA Label Actually Says About Drug Interactions

The Evenity prescribing information (2019, revised 2020) states in Section 7 (Drug Interactions): "No drug-drug interaction studies have been conducted with romosozumab" [1]. This reflects the standard biologic monoclonal antibody position: because the drug does not use small-molecule metabolic pathways, formal DDI trials are generally not conducted.

The label's Section 5.1 cardiovascular warning reads in relevant part: "Romosozumab may increase the risk of MI, stroke, and cardiovascular death. In the ARCH trial, a higher rate of serious cardiovascular events was observed in the romosozumab group compared to the alendronate group" [1].

The absence of a specific cannabis warning in the label does not indicate safety. It indicates the interaction has not been studied, which is a different clinical category.

Practical Guidance for Patients and Prescribers

Before Starting Romosozumab

Conduct a full cardiovascular history. The FDA-mandated contraindication covers MI or stroke within the preceding year. For patients with more remote cardiovascular events or multiple risk factors, document a shared decision-making conversation about MACE risk. Ask specifically about cannabis use frequency, route, and product type (THC-dominant vs. CBD-dominant vs. Balanced).

During the 12-Month Treatment Course

Monitor blood pressure and resting heart rate at each of the 12 monthly injection visits. Patients who smoke or vape THC should be counseled to avoid use on injection days and for 24 to 48 hours afterward, during the period when subcutaneous absorption of romosozumab peaks (serum peak at approximately 5 days post-injection per the label pharmacokinetic data) [1]. This is not a pharmacokinetic precaution but a cardiovascular one: avoid stacking acute sympathetic surges during the post-injection period.

Ensure calcium 1,000 to 1,200 mg/day and vitamin D 800 to 1,000 IU/day supplementation are ongoing [11]. These directly affect the anabolic response and are within patient control.

After Completing the 12 Injections

Transition immediately to an antiresorptive agent. Denosumab or a bisphosphonate should start within 1 month of the last romosozumab injection to preserve BMD gains [12]. Cannabis does not affect this sequencing decision, but the prescriber should reassess cardiovascular risk profile at the transition point.

Summary of Interaction Evidence Quality

| Interaction | Evidence Level | Primary Concern | Action | |---|---|---|---| | THC + romosozumab (cardiovascular) | Indirect (mechanistic) | MACE risk overlap | Reduce/pause THC during treatment in Tier 2 and 3 patients | | CBD + romosozumab (pharmacokinetic) | Not applicable | No CYP overlap | No direct romosozumab PK effect | | CBD + co-medications (CYP2C9) | Moderate (pharmacokinetic) | Warfarin, statin level elevation | Monitor INR and statin side effects | | THC + bone metabolism (osteoblast CB1) | Preclinical only | Attenuated anabolic response | Counsel; no hard contraindication | | Alcohol (heavy) + bone metabolism | Epidemiologic | Reduced osteoblast activity | Strongly discourage heavy use | | Alcohol (moderate) + romosozumab | Low/indirect | Negligible | No hard contraindication |